

	Month (%)	Quarter (%)	FYTD (%)	1 Year (% p.a.)	2 Years (% p.a.)	3 Years (% p.a.)	Since Inception^ (% p.a.)	Inception Cumulative^ (%)
Perennial Better Future Trust (Net)	-0.3	4.9	-0.3	36.6	17.6	14.6	15.2	64.2
S&P/ASX Small Ordinaries Accum. Index	0.7	4.1	0.7	32.3	10.0	9.2	9.1	35.7
Value Added	-1.0	0.8	-1.0	4.3	7.6	5.4	6.1	28.4

[^]Since inception: 1 February 2018. Past performance is not a reliable indicator of future performance.

Overview

- The Better Future Trust was down 0.3% net of fees in July, underperforming the benchmark return by 1.0%.
- It is over three years since the inception of the Trust. It is a key goal of the Trust to demonstrate that there is no performance trade-off to invest with a focus on shaping a better future. Since inception in February 2018, the Trust has delivered a 15.2% p.a. return net of fees, outperforming the benchmark by 6.1% p.a.
- Positive contributors this month included 4D Medical (+25.7%), MedAdvisor (+16.7%), Genetic Signatures (+13.6%) and Calix (+4.1%).
- Negative contributors this month included Immutep (-12.7%), Kathmandu (-10.6%), Janison Education (-7.9%) and Imricor Medical Systems (-14.8%).

Perennial Better Future Trust

The aim of the Trust is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or businesses that are making a positive contribution to creating a better future. The Trust seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index measured on a rolling three-year basis.

Portfolio Manager
Damian Cottier

APIR Code
WPC5600AU


Distribution Frequency
Half yearly (if any)

Minimum Initial Investment
\$25,000

Trust Inception Date
1 February 2018

Fees
1.20% p.a. + Performance fee

Portfolios Contribution to the UN Sustainable Development Goals



Source: Data provided by the Sustainable Platform 30 Sept 2020; based on company revenues. Note: ~70% of holding companies revenue contributes to the UN SDGs

Better Future Highlight

New Zealand renewable energy generator, Meridian Energy, announced that it was seeking registrations of interest to develop a green hydrogen plant on the New Zealand's South Island.

While green hydrogen is still a developing technology, it is regarded as one of the most promising energy sources to decarbonise heavy transportation and hard-to-abate industrial industries that currently rely on fossil fuels to generate heat energy. Green hydrogen is produced by using renewable electricity to split water into hydrogen energy. A key challenge for the technology is to have a significant, consistent source of renewable energy. Meridian's hydro generation is well suited to this and the company is seeking expressions of interest to supply electricity to a green energy hydrogen project as an alternative to the current electricity supply agreement with the New Zealand Aluminium Smelter which is up for renewal in 2024.

The proposed plant would be up to 600 megawatts which would be the world's largest green hydrogen plant.

Given the level of interest globally in progressing green hydrogen technology, it will be interesting to see if a viable project will evolve here. A viable project will likely require assistance in one form or another given existing technology – although the efficiency of the technology is likely to rapidly improve over the next decade, much like solar and wind development over the past decade.

Performance Since Inception



Value of A\$100,000 since inception (1 February 2018) of the Better Future Trust as at 31 July 2021.

Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

Trust Review

The Better Future Trust was down 0.3% net of fees in July, underperforming the benchmark return by 1.0%.

It is over three years since the inception of the Trust. It is a key goal of the Trust to demonstrate that there is no performance trade-off to invest with a focus on shaping a better future. Since inception in February 2018, the Trust has delivered a 15.2% p.a. return net of fees, outperforming the benchmark by 6.1% p.a.

Positive contributors this month included 4D Medical (+25.7%), MedAdvisor (+16.7%), Genetic Signatures (+13.6%) and Calix (+4.1%).

Negative contributors this month included Immutech (-12.7%), Kathmandu (-10.6%), Janison Education (-7.9%) and Imricor Medical Systems (-14.8%).

4D Medical announced that it had made good progress during the June quarter and now has eight clinical trials of the company's XV Lung Ventilation Analysis Software secured with leading hospitals and medical institutions. These include the John Hopkins School of Medicine which is studying the clinical benefit of the software in treating patients with chronic obstructive pulmonary disease which is the third highest cause of death in the world.

MedAdvisor announced that it had secured a 5-year agreement with Australian Pharmaceutical Industries which owns Priceline Pharmacy, Soul Pattison Chemist and Pharmacist Advice pharmacy banner groups. This will add over 250 pharmacies to the MedAdvisor platform which allows pharmacists and their patients to manage medications safely and effectively.

Calix signed two memoranda of understanding during the month to develop the company's carbon dioxide separation technology. The first is with UK lime company Tarmac to develop a Calix calciner for lime production with carbon dioxide capture. The second is with RHI Magnesita which is a leading global supplier of refractory products – these are products resistant to intense temperatures. This MOU relates to a commercial scale demonstration facility for carbon dioxide separation for the refractory materials production process which is a highly carbon intensive process.

Kathmandu was weaker due to the likely impact of the longer than expected COVID-related lockdowns in New South Wales. Imricor was weaker after confirming that the stop-start COVID reopening in the northern hemisphere, particularly in Europe, was having ongoing impacts on the business.

During the month we added Opthea to the portfolio. Opthea is developing a treatment for "wet" age-related macular degeneration in patients who typically respond sub-optimally to existing treatments. Age-related macular degeneration causes progressive loss of central vision and, in Australia, is responsible for half of all blindness and severe vision loss. During the month Opthea announced that the US Food and Drug Administration, has granted Fast Track designation for the company's product which is a process that expedites the FDA's review for therapies for serious conditions for which there is an unmet medical need.

During the month we participated in EROAD's capital raising to acquire Coretex which is a company with efficiency-monitoring technology for specialist transportation such as refrigerated trucks. The Coretex offering is highly complementary to EROAD's existing product offering.

Other portfolio changes during the month included increasing the portfolio holding in 4D Medical and reducing holdings in Resmed and Bendigo Bank after recent strong performance.

At month end the Trust held 47 stocks and cash was 9.0%.

At the end of July, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Trust was 7.2 which is 25% higher than the benchmark ESGE Score of 5.7.

ESG Activity

Relevant ESG activity during the month included:

- Engagement with EROAD on proxy voting, remuneration disclosure and gender diversity.
- Engagement with NearMap (not held) on carbon emissions mapping and reporting.
- Damian was a guest speaker at a session on impact investing at the Centre for Social Impact at the University of New South Wales.
- We participated in the IAST (Investors Against Slavery and Trafficking) Asia Pacific modern slavery collaboration quarterly meeting.

Top 5 Active Positions Trust (%) Index (%)

Integral Diagnostics	4.1	0.3
Spark NZ	4.1	0.4
Immutech	3.1	0.0
Meridian Energy	3.0	0.0
Calix	2.9	0.0

Better Future and ESG Team

Damian Cottier
Portfolio Manager

Emilie O'Neill
ESG & Equities
Analyst



CERTIFIED BY RIAA



The Perennial Better Future Trust has been certified by the Responsible Investment Association Australasia according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See www.responsiblereturns.com.au for details¹.

1. The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

Invest Online Now

Contact Us



Level 27, 88 Phillip Street, Sydney NSW 2000



invest@perennial.net.au



www.perennial.net.au



1300 730 032

Signatory of:



Proud member of the
Responsible Investment
Association Australia (RIAA)



Issued by: The Investment Manager, Perennial Value Management Limited, ABN 22 090 879 904, AFSL: 247293. Responsible Entity: Perennial Investment Management Limited ABN 13 108 747 637, AFSL: 275101. This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation. While every effort has been made to ensure the information in this promotional statement is accurate, its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Gross performance does not include any applicable management fees or expenses. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. Contractual arrangements, including any applicable management fee, may be negotiated with certain large investors. Investments in the Trusts must be accompanied by an application form. The current relevant product disclosure statements, additional information booklet and application forms can be found on Perennial's website www.perennial.net.au.